{'fraction_non_alphanumeric': 0.016129032258064516, 'fraction_numerical': 0.00576036866359447, 'mean_word_length': 5.297101449275362, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Myasthenia gravis and pregnancy.

Introduction Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by varying degrees of weakness in the skeletal muscles of the body. It is caused by the development of autoantibodies directed against the nicotinic acetylcholine receptor in the postsynaptic portion of the neuromuscular junction. Although a rare disease, MG is the most common primary disorder of neuromuscular transmission with prevalence ranges from 50 to 125 cases per million population. Whereas genetic factors are usually involved with autoimmune disease, there are no significant human leukocyte antigen (HLA) types associated with this disease. Myasthenia gravis affects twice as many women as men, with the peak incidence in women occurring in the third decade of life as compared with men, in whom it occurs in the sixth and seventh decade.